HC Wainwright Has Pessimistic Outlook of ETON Q2 Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Analysts at HC Wainwright decreased their Q2 2025 earnings estimates for Eton Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $0.08 per share for the quarter, down from their previous estimate of $0.17. HC Wainwright has a "Buy" rating and a $33.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals' Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.42 EPS, FY2026 earnings at $1.57 EPS, FY2027 earnings at $1.85 EPS, FY2028 earnings at $2.87 EPS and FY2029 earnings at $3.74 EPS.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The business had revenue of $11.65 million for the quarter, compared to the consensus estimate of $10.53 million.

ETON has been the topic of a number of other reports. Craig Hallum raised their price objective on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a "buy" rating in a report on Wednesday, March 19th. B. Riley restated a "buy" rating and issued a $24.00 price target (up from $21.00) on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.

Remove Ads

Eton Pharmaceuticals Stock Performance

NASDAQ ETON traded down $1.05 during trading hours on Friday, reaching $13.74. 170,017 shares of the company's stock were exchanged, compared to its average volume of 160,487. The company has a market capitalization of $368.48 million, a price-to-earnings ratio of -62.45 and a beta of 1.37. Eton Pharmaceuticals has a one year low of $3.03 and a one year high of $18.41. The company's 50-day moving average is $15.60 and its two-hundred day moving average is $11.77.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Eton Pharmaceuticals during the 3rd quarter worth approximately $54,000. Tower Research Capital LLC TRC bought a new stake in shares of Eton Pharmaceuticals during the fourth quarter worth approximately $86,000. Jane Street Group LLC acquired a new stake in Eton Pharmaceuticals during the 3rd quarter worth approximately $90,000. Jefferies Financial Group Inc. acquired a new position in Eton Pharmaceuticals in the 4th quarter valued at $133,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Eton Pharmaceuticals in the fourth quarter valued at about $147,000. Institutional investors own 27.86% of the company's stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.